Evidence map›Paper›PMID 39235441›Full record

ArticleTherapeutic advances in respiratory disease

Association between acute exacerbation and progressive pulmonary fibrosis in interstitial lung disease: a retrospective cohort study.

Liying Zhai, Zhiqiang Wang, Wencheng Yu

Abstract read
In one paragraph

Article in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Liying ZhaiDepartment of Pulmonary and Critical Care Medicine, the affiliated hospital of Qingdao University, Qingdao, China.
Zhiqiang WangQilu Hosp Shandong Univ, Dept Pulm &Crit Care Med, Qingdao Affiliation Shandong University, Jinan, Shandong, China.
Wencheng YuDepartment of Pulmonary and Critical Care Medicine, the affiliated hospital of Qingdao University, Qingdao 266003, China.ORCID 0000-0001-8064-4145

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute exacerbation (AE) refers to rapidly progressive respiratory deterioration in the clinical course of interstitial lung disease (ILD). Progressive pulmonary fibrosis (PPF) is the chronic progressive phenotype of ILD. No study has investigated the relationship between AE and PPF in ILD.

objectivesWe aimed to determine the association between AE and PPF in ILD patients.

designA retrospective cohort study.

methodsA total of 414 patients hospitalised for ILD were included in our study. The clinical presentations, radiographic features and laboratory findings of the patients were reviewed.

resultsAE was present in 120 (29.0%) ILD patients and was associated with a higher risk of death than non-AE patients in the whole cohort (HR 2.893; 95% CI, 1.847-4.529;

conclusionIn the context of ILD, both AE and PPF were found to be associated with poor prognosis. However, the adverse effect of AE on prognosis disappeared when PPF was considered as a stratification feature, whereas the adverse effect of PPF on prognosis persisted in both AE and non-AE individuals. Therefore, it is important to investigate effective strategies to prevent disease progression after AE. Increased recognition and attention to PPF and early antifibrotic therapy at the appropriate time is also warranted.

Indexed as

Disease ProgressionLung Diseases, InterstitialPulmonary FibrosisAgedAged, 80 and overFemaleHumansLungMaleMiddle AgedPrognosisRetrospective StudiesRisk FactorsTime Factorsacute exacerbationinterstitial lung diseasesprognosisprogressive pulmonary fibrosis

Identifiers

PMID39235441
PMCPMC11378212

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.